We describe results in unresectable pancreatic tumors treated with USgHIFU hyperthermia ablation plus adjuvant chemotherapy.
Materials and methods
Forty three cases of non resectable pancreatic tumors were treated from March 2010 to March 2013, and all of them underwent systemic chemotherapy. Clinical responses (thermical ablation achieved) were measured by image techniques. They were 29 Stage III cases and 14 Stage IV cases. Complications were also analyzed.
Results
Clinical responses (ablation obtained) were 82% in all cases, sustained at 8 weeks of the procedure. We obtained 10 complete responses (25%) at the end of the combined treatment, 9 from stage III patients and 2 from stage IV. Major complications included severe pancreatitis with GI bleeding (1), skin burning grade III that required plastic surgery (2). No deaths were registered. Median Survival was 13 month (6 mo - 2.7 year).
Conclusion
HIFU plus SC is a potentially effective and safe modality for the treatment of unresectable pancreatic cancer.
Author information
Authors and Affiliations
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Vidal-Jove, J., Perich, E., Garcia-Bernal, M. et al. Hyperthermic ablation by UltraSound Guided High Intensity Focused Ultrasound (USgHIFU) plus Systemic Chemotherapy (SC) for locally advanced pancreatic cancer: the secret of longer survival. J Ther Ultrasound 2 (Suppl 1), A6 (2014). https://doi.org/10.1186/2050-5736-2-S1-A6
Published:
DOI: https://doi.org/10.1186/2050-5736-2-S1-A6